Potential roles of RNA N6-methyladenosine (m6A) modification in tumour microenvironment (TME) cell infiltration has been demonstrated in recent studies. Nonetheless, the mechanism of its regulation remains unknown and immunotherapy has been marginal in prostate cancer. We demonstrated the expression of different m6A regulators within prostate cancer related to genetic variation, alternative splicing (AS), tumour mutational burden (TMB) and TME. Unsupervised clustering and risk prediction model constructed by 24 m6A regulators could predict scores of TME and prostate cancer patients prognosis. T cells CD8 was the intersection of immune cells which are related to multiple biological processes, and the fraction of T cells CD8 strongly correlates with immune associated gene sets. m6A methylation modification and immune cells infiltration played a nonnegligible role in prostate cancer. Our study represents a step towards personalized immunotherapy for prostate cancer patients.

中文翻译：

---

前列腺癌中RNA m6A甲基化调节剂和肿瘤免疫细胞浸润特性的分析。

在最近的研究中已经证明了RNA N6-甲基腺苷（m6A）修饰在肿瘤微环境（TME）细胞浸润中的潜在作用。然而，其调节机制仍是未知的，并且免疫疗法在前列腺癌中一直是微不足道的。我们证明了与基因变异，选择性剪接（AS），肿瘤突变负担（TMB）和TME相关的前列腺癌中不同m6A调节剂的表达。由24个m6A调节器构建的无监督聚类和风险预测模型可以预测TME评分和前列腺癌患者的预后。T细胞CD8是与多个生物学过程相关的免疫细胞的交集，并且T细胞CD8的比例与免疫相关基因集密切相关。m6A甲基化修饰和免疫细胞浸润在前列腺癌中起着不可忽略的作用。我们的研究代表了针对前列腺癌患者的个性化免疫治疗迈出的一步。